ライフサイエンスコーパス: atrial natriuretic factor

1 anges, including activation of genes such as atrial natriuretic factor.

2 tricular output, and possibly high levels of atrial natriuretic factor.

3 icular expression of the load-sensitive gene atrial natriuretic factor.

4 They also express the gene for atrial natriuretic factor.

5 e an 8-fold increase in ventricular mRNA for atrial natriuretic factor.

6 osin heavy chain, myosin light chain 2v, and atrial natriuretic factor.

7 nduction of fetal genes such as betaMyHC and atrial natriuretic factor.

8 d expression of the hypertrophic marker gene atrial natriuretic factor.

9 lmonary congestion and had reduced levels of atrial natriuretic factor.

10 ricles expressed beta-myosin heavy chain and atrial natriuretic factor.

11 y reduced ET-1- and PE-induced expression of atrial natriuretic factor.

12 e, sarcomeric organization, and induction of atrial natriuretic factor.

13 CNP and (Cys18)-atrial natriuretic factor (4-23) amide (cANF(4-23)) elic

14 ed in the morphants including an increase in atrial natriuretic factor, a hallmark for cardiac hypert

15 we find that fluorescence from Topaz-tagged atrial natriuretic factor, a peptidergic vesicle pH indi

16 LV fibrosis, and expression of fetal genes (atrial natriuretic factor, alpha-skeletal muscle actin,

17 spholamban restored the expression levels of atrial natriuretic factor and alpha-skeletal actin mRNA

18 function and decreased cardiac expression of atrial natriuretic factor and alpha-skeletal actin mRNA.

19 n neonatal hearts, ventricular expression of atrial natriuretic factor and alpha-skeletal actin was m

20 ore, mRNA expressions of the embryonic genes atrial natriuretic factor and alpha-skeletal actin were

21 arkers of hypertrophy, alpha-skeletal actin, atrial natriuretic factor and beta-MyHC, were upregulate

22 ell area, protein content, and the mRNAs for atrial natriuretic factor and beta-MyHC.

23 ificantly increased heart/body weight ratio, atrial natriuretic factor and beta-myosin heavy chain mR

24 hearts demonstrate significant induction of atrial natriuretic factor and beta-myosin heavy chain tr

25 e cross-sectional areas, hypertrophy markers atrial natriuretic factor and beta-myosin heavy chain).

26 ition, two cardiac hypertrophy marker genes, atrial natriuretic factor and beta-myosin heavy chain, w

27 en synthesis and hypertrophy markers such as atrial natriuretic factor and beta-myosin heavy chain.

28 enuated expression of the trabecular markers atrial natriuretic factor and bone morphogenic protein 1

29 el pathways associated with up-regulation of atrial natriuretic factor and brain natriuretic peptide

30 ist-induced expression of the embryonic gene atrial natriuretic factor and enlargement of cardiomyocy

31 f the expression of various genes, including atrial natriuretic factor and Ifi204 (encoding p204).

32 d and endothelin-1-mediated induction of the atrial natriuretic factor and myosin light chain-2 genes

33 It prevented PE-stimulated increases in atrial natriuretic factor and myosin light chain-2 mRNA

34 activated reporter expression from both the atrial natriuretic factor and myosin light chain-2 ventr

35 trophy, increased expression of fetal genes (atrial natriuretic factor and skeletal alpha-actin), dec

36 accompanied by enhanced expression of prepro-atrial natriuretic factor and skeletal alpha-actin.

37 cardiac expression of HF marker genes (GRK2, atrial natriuretic factor, and beta-myosin heavy chain).

38 yosin heavy chain, cardiac troponin I and T, atrial natriuretic factor, and cardiac transcription fac

39 ncrease in cell size, elevated expression of atrial natriuretic factor, and induction of sarcomere or

40 RNA expression of brain natriuretic peptide, atrial natriuretic factor, and renin were significantly

41 m cardiac enzymes, plasma catecholamines and atrial natriuretic factor, and SaO2.

42 i.e. those for c-Fos, skeletal alpha-actin, atrial natriuretic factor, and the alpha3-subunit of Na+

43 19%), secreted more apoB, and expressed less atrial natriuretic factor (ANF) and brain natriuretic pe

44 5 haploinsufficiency also markedly decreased atrial natriuretic factor (ANF) and connexin 40 (cx40) t

45 function, its synergism with partners at the atrial natriuretic factor (ANF) and connexin-40 (Cx40) p

46 are markers of cardiac hypertrophy including atrial natriuretic factor (ANF) and myosin light chain-2

47 (GSK3beta) is critical for transcription of atrial natriuretic factor (ANF) by beta-adrenergic recep

48 The promoter-enhancer region of the atrial natriuretic factor (ANF) contains several putativ

49 induced increases in NADPH oxidase activity, atrial natriuretic factor (ANF) expression, and cardiac

50 promoter/luciferase reporter genes, increase atrial natriuretic factor (ANF) expression, and promote

51 terized by transcriptional activation of the atrial natriuretic factor (ANF) gene and enlargement (hy

52 IL-18 has also been shown to induce atrial natriuretic factor (ANF) gene expression in adult

53 The atrial natriuretic factor (ANF) gene is initially expres

54 otic expression screen for activators of the atrial natriuretic factor (ANF) gene, a cardiac-specific

55 In the cardiac atrial natriuretic factor (ANF) gene, a promoter-proxima

56 its DNA binding sites in the promoter of the atrial natriuretic factor (ANF) gene, an in vivo target

57 immediate early genes, and up-regulates the atrial natriuretic factor (ANF) gene, but does not affec

58 h considerable evidence indicates a role for atrial natriuretic factor (ANF) in renal salt regulation

59 Atrial natriuretic factor (ANF) inhibits proliferation i

60 Atrial natriuretic factor (ANF) is abundantly expressed

61 In contrast, while MnTMPyP inhibited basal atrial natriuretic factor (ANF) mRNA expression, the str

62 Phenylephrine-induced activation of the atrial natriuretic factor (ANF) promoter (measured by th

63 ed protein content, [3H] leucine uptake, and atrial natriuretic factor (ANF) promoter activity.

64 containing c-Jun and with the cardiomyocyte atrial natriuretic factor (anf) promoter and the cardiac

65 We report here that the atrial natriuretic factor (ANF) promoter is a target of

66 can induce reporter gene expression from the atrial natriuretic factor (ANF) promoter, a genetic mark

67 vation of cardiac gene promoters such as the atrial natriuretic factor (ANF) promoter.

68 ignificance of this interaction, we used the atrial natriuretic factor (ANF) promoter.

69 Both inhibitors markedly attenuated atrial natriuretic factor (ANF) reporter gene expression

70 We examined the mechanism of atrial natriuretic factor (ANF) transcription by isoprot

71 bx20, activates a cardiac-specific promoter (atrial natriuretic factor (ANF)) alone and synergistical

72 weight/body weight ratio, elevated levels of Atrial Natriuretic Factor (ANF), and altered expression

73 messenger ribonucleic acid (mRNA) levels of atrial natriuretic factor (ANF), beta-myosin heavy chain

74 These include atrial natriuretic factor (ANF), beta-myosin heavy chain

75 embryonic hearts expressed similar levels of atrial natriuretic factor (ANF), brain natriuretic pepti

76 cular expression of several genes, including atrial natriuretic factor (ANF), has been documented in

77 Zic3(null/y) embryonic stem cells including atrial natriuretic factor (ANF), Nkx2.5 and Tbx5.

78 perated with c-Raf to increase expression of atrial natriuretic factor (ANF), whereas N17Rac1 inhibit

79 tivator of p38, stimulated the expression of atrial natriuretic factor (ANF), which is a genetic mark

80 We found that atrial natriuretic factor (ANF), which is normally expre

81 , and reexpression of the embryonic gene for atrial natriuretic factor (ANF).

82 des expression of the cardiac-specific gene, atrial natriuretic factor (ANF).

83 ion of cardiac-specific genes, including the atrial natriuretic factor (ANF).

84 ve mRNA levels of the hypertrophy-associated atrial natriuretic factor (ANF, 2.1-fold) and skeletal a

85 nduced expression of two hypertrophic genes (atrial natriuretic factor [ANF] and c-myc) and also enha

86 al hydrolysis of ligand (125I-labeled native atrial natriuretic factor, ANF1-28), and receptor recycl

87 pregulation of hypertrophy markers including atrial natriuretic factor, beta-MHC, and GATA4; and acti

88 onic and contractile protein genes including atrial natriuretic factor, beta-myosin heavy chain, and

89 expression of the hypertrophic marker genes, atrial natriuretic factor, brain natriuretic peptide, an

90 rization ability inhibited the activation of atrial natriuretic factor by wild-type CSX/NKX2.5.

91 We investigated the potential of a C-type atrial natriuretic factor (C-ANF) to image developing pl

92 of mRNAs for fetal type myosin heavy chain, atrial natriuretic factor, c-fos, transforming growth fa

93 ently, we reported the (64)Cu-labeled C-type atrial natriuretic factor (CANF) fragment for detecting

94 pressed genes including cardiac alpha actin, atrial natriuretic factor, cardiac myosin heavy chain al

95 o well-known markers of cardiac hypertrophy (atrial natriuretic factor, CARP, and beta-myosin heavy c

96 , overexpression of NF-kappaB itself induced atrial natriuretic factor expression and cardiomyocyte e

97 heart-to-body weight ratios with ventricular atrial natriuretic factor expression denoting myocardial

98 ment, sarcomeric organization, and increased atrial natriuretic factor expression in association with

99 P79 attenuated cardiomyocyte hypertrophy and atrial natriuretic factor expression in response to angi

100 Hypertrophy and atrial natriuretic factor expression induced by angioten

101 Atrial natriuretic factor expression was approximately 6

102 ng Ras-induced myofibrillar organization and atrial natriuretic factor expression was only minimally

103 ha(1B)AR-induced hypertrophy and ventricular atrial natriuretic factor expression were significantly

104 ction, which induced myocyte hypertrophy and atrial natriuretic factor expression, protected against

105 t, cardiomyocyte diameter, and inhibition of atrial natriuretic factor expression.

106 hanced sarcomeric organization, and elevated atrial natriuretic factor expression.

107 ficant reduction in NF-kappaB activation and atrial natriuretic factor expression.

108 ed protein synthesis, cell surface area, and atrial natriuretic factor expression.

109 In contrast, secretion of atrial natriuretic factor from ventricular myocytes was

110 MAPK cascade, and (c) induction of c-fos or atrial natriuretic factor gene occurred partly through t

111 ocardin A transactivated the promoter of the atrial natriuretic factor gene through the serum respons

112 ssion of cardiac-specific promoters from the atrial natriuretic factor gene, the b-type natriuretic p

113 n, whereas it did not increase expression of atrial natriuretic factor gene.

114 ithin the proximal promoter -242 site of the atrial natriuretic factor gene.

115 ytosis were developed by expressing a prepro-atrial natriuretic factor-green fluorescent protein fusi

116 ganization, increased cell size, and induced atrial natriuretic factor in cardiomyocytes plated on th

117 els of cardiac hypertrophy and expression of atrial natriuretic factor in Mekk1(-/-) animals, which s

118 s-sectional area, and hypertrophy-associated atrial natriuretic factor induction following pressure o

119 days) did not affect the trophic response or atrial natriuretic factor induction to pressure overload

120 c mass, myocyte size, hypertrophy-associated atrial natriuretic factor induction, and c-Jun N-termina

121 The C3 treatment inhibited Ang II-induced atrial natriuretic factor induction, whereas it had no e

122 r studies of singular prevention strategies (atrial natriuretic factor, loop diuretics, dopamine, man

123 iferase gene expression but no activation of atrial natriuretic factor-luciferase gene expression.

124 accumulation, coincident with activation of atrial natriuretic factor-luciferase gene expression.

125 O mice shows a dramatic up-regulation of the atrial natriuretic factor message, a well-established bi

126 ET-1 also induced a significant increase in atrial natriuretic factor mRNA expression as well as in

127 here were no significant changes in IGF-1 or atrial natriuretic factor mRNA levels in response to GH

128 There was also an increase in ventricular atrial natriuretic factor mRNA levels, demonstrating act

129 ttenuate increased ventricular expression of atrial natriuretic factor mRNA.

130 n reaction, we measured transcript levels of atrial natriuretic factor, myosin heavy chain-alpha and

131 - the natriuretic peptides - referred to as atrial natriuretic factor or atrial natriuretic peptide

132 with the rat, none of these agents increased atrial natriuretic factor or beta-MyHC mRNAs.

133 mg/mm; p<0.001) and reduced LV expression of atrial natriuretic factor (p<0.05), alpha-skeletal muscl

134 hy like: alpha- and beta-myosin heavy chain, atrial natriuretic factor, phospholamban, and sarcoplasm

135 in cell size, sarcomeric reorganization, and atrial natriuretic factor production were remarkably att

136 ponse when assessed by protein synthesis and atrial natriuretic factor production, a marker gene of h

137 Serum increased atrial natriuretic factor promoter activity and cell siz

138 We tested atrial natriuretic factor promoter activity as a positiv

139 as co-transfected with SRF, but it repressed atrial natriuretic factor promoter activity, which was s

140 P-TF2dependent synergistic activation of the atrial natriuretic factor promoter by both GATA4 and the

141 educed the capability of SRF to activate the atrial natriuretic factor promoter that contains the ser

142 that CARP inhibits Nkx2.5 transactivation of atrial natriuretic factor promoter.

143 hat Tip60 and SRF cooperatively activate the atrial natriuretic factor promoter.

144 novel VEGF-B167 transgene controlled by the atrial natriuretic factor promoter.

145 onal responsiveness of ELK-1, GATA4, and the atrial natriuretic factor promoter.

146 arcomeric units and in the expression of the atrial natriuretic factor protein.

147 and of the other retinal guanylate cyclase, atrial natriuretic factor-receptor guanylate cyclase.

148 onomous accumulation of the endocytic tracer atrial natriuretic factor-red fluorescent protein at ear

149 that TBX5 activates the transcription of an atrial natriuretic factor reporter construct and this ef

150 ons of the genes of skeletal alpha-actin and atrial natriuretic factor, repression of the gene of the

151 omains inhibited the adrenergically mediated atrial natriuretic factor response.

152 Ventricular expression of mRNAs for atrial natriuretic factor, skeletal alpha-actin, and bet

153 However, in vivo imaging of a neuropeptide, atrial natriuretic factor, tagged with green fluorescent

154 iomyocytes suppresses cardiac troponin C and atrial natriuretic factor transcription.

155 Moreover, the expression of atrial natriuretic factor, used as a molecular marker of

156 Atrial natriuretic factor-VEGF-B167 expression was low i

157 Atrial natriuretic factor was expressed in the TG ventri

158 cific markers desmin, sarcomeric myosin, and atrial natriuretic factor was similar to that of culture

159 Expression of fetal-type genes, such as atrial natriuretic factor, was also significantly lower

160 ing adult heart, steady-state mRNA levels of atrial natriuretic factor were increased in both the fet

161 Except for atrial natriuretic factor, which correlated weakly (r =

162 Atrial natriuretic factor, which signals via cGMP, also